-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo's Wegovy Shows Efficacy in Children With Obesity in Late-stage Study

MT Newswires·11/16/2026 10:38:46
Listen to the news
10:38 AM EST, 11/16/2026 (MT Newswires) -- Novo Nordisk's (NOVO-B.CO) investigational semaglutide injection, marketed as Wegovy, in combination with a reduced-calorie diet and increased physical activity, showed efficacy in reducing the body mass index, or BMI, of children aged six to under 12 with obesity in the phase 3 Step Young study. The late-stage trial demonstrated a 17.4% reduction in BMI from baseline after 68 weeks of treatment, compared with a 2.2% increase with placebo, based on the efficacy estimand, according to a Monday release. Almost 80% of children taking Wegovy recorded a BMI reduction of at least 10%, compared with none in the placebo group. An estimated 83% also registered an improvement in BMI category, compared with 23.5% in the placebo group. The Danish drugmaker said Wegovy's overall safety and tolerability profile in the trial were consistent with findings from previous pediatric and adult studies, with no new safety concerns identified.